课题基金 / 基金详情

Non-Immunogenic Peptide Anticoagulant

Non-Immunogenic Peptide Anticoagulant
非免疫原性肽抗凝剂
批准号:
6691111
负责人:
DAVID Henry FARRELL
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-20 至 2004-07-31

项目摘要

项目成果

DAVID Henry FARRELL的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We have identified a novel heparin-like peptidyl coagulation inhibitor that is a peptide fragment of a naturally-occurring human fibrinogen isoform, gammaA/gamma' fibrinogen. The peptide is active as an anticoagulant in whole plasma, and is unlikely to elicit an immune response, since it is a normal fibrinolytic cleavage product of this fibrinogen isoform. This application focuses on the development of this peptide as a potential pharmacologic anticoagulant. This peptide anticoagulant would have significant advantages over heparin, and could be used as a general replacement for heparin, particularly when heparin is clinically contraindicated, as in cases of heparin-induced thrombocytopenia. The specific aims are therefore to: I) Express the gamma' chain peptide in a recombinant expression system. II) Assay the recombinant gamma1,' peptide for anticoagulant and anti-platelet activities. At the conclusion of these studies, essential milestones will be achieved for Phase II development of the gamma' peptide as a pharmacologic anticoagulant.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels
  • 批准号:
    10759950
  • 项目类别:
  • 资助金额:
    $27.77万
  • 财政年份:
    2023
  • 负责人:
    DAVID Henry FARRELL
  • 依托单位:
Venous Thromboembolism Risk Marker Assay
  • 批准号:
    8249829
  • 项目类别:
  • 资助金额:
    $52.03万
  • 财政年份:
    2010
  • 负责人:
    DAVID Henry FARRELL
  • 依托单位:
Venous Thromboembolism Risk Marker Assay
  • 批准号:
    8131995
  • 项目类别:
  • 资助金额:
    $52.03万
  • 财政年份:
    2010
  • 负责人:
    DAVID Henry FARRELL
  • 依托单位:
Venous Thromboembolism Risk Marker Assay
  • 批准号:
    7998652
  • 项目类别:
  • 资助金额:
    $51.42万
  • 财政年份:
    2010
  • 负责人:
    DAVID Henry FARRELL
  • 依托单位: